Subscribe to Entrepreneur for $5
Subscribe

Jefferies (JEF) Q4 Earnings and Revenues Lag Estimates

Jefferies (JEF) delivered earnings and revenue surprises of -2.86% and 4.96%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

By
This story originally appeared on Zacks

Jefferies (JEF) came out with quarterly earnings of $1.36 per share, missing the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.11 per share a year ago. These figures are adjusted for non-recurring items.

- Zacks

This quarterly report represents an earnings surprise of -2.86%. A quarter ago, it was expected that this investment banking and capital markets company would post earnings of $1.02 per share when it actually produced earnings of $1.51, delivering a surprise of 48.04%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Jefferies, which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $1.81 billion for the quarter ended November 2021, missing the Zacks Consensus Estimate by 4.96%. This compares to year-ago revenues of $1.86 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Jefferies shares have added about 6.8% since the beginning of the year versus the S&P 500's decline of -1.1%.

What's Next for Jefferies?

While Jefferies has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Jefferies: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #1 (Strong Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1 on $1.59 billion in revenues for the coming quarter and $3.84 on $6.38 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Miscellaneous Services is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Primis Financial (FRST), another stock in the same industry, has yet to report results for the quarter ended December 2021.

This holding company for Sonabank is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Primis Financial's revenues are expected to be $25.99 million, down 22.7% from the year-ago quarter.



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Jefferies Financial Group Inc. (JEF): Free Stock Analysis Report

 

Primis Financial Corp. (FRST): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research